PDCD1 and cancer: Immune checkpoint inhibitors (ICIs), such as anti–programmed cell death-1 (anti–PD-1), anti–programmed cell death ligand (anti–PD-L1), and anti–cytotoxic T lymphocyte–associated protein 4 (anti–CTLA-4) antibodies, are now a standard of care for some previously incurable cancers (3).